The ‘Holy Grail’ in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

Andreas Schläpfer*, Christian Auclair, Bassam Janji, Manale Karam, Muhammad Zaeem Noman

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biopôle, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We are about to start clinical trials with two of four leading-edge cancer drugs mainly focusing on immune-oncology and tumor vascular normalization with multi-billion $ sales potential. Here, we present our strategy and one of our pioneering drug candidates that has already shown exceptional results with tumor cell conditioning to improve the efficacy of immune checkpoint inhibitors.

Original languageEnglish
Pages (from-to)771-775
Number of pages5
JournalChimia
Volume74
Issue number10
DOIs
Publication statusPublished - Oct 2020

Keywords

  • AC Bioscience SA
  • ACB1801
  • Cancer therapies
  • Immune checkpoint inhibitors
  • Swiss biotech

Fingerprint

Dive into the research topics of 'The ‘Holy Grail’ in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy'. Together they form a unique fingerprint.

Cite this